Paramyotonia Congenita Clinical Trial
OBJECTIVES:
I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in
patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic
paralysis, and hypokalemic periodic paralysis.
PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are stratified by
participating institution and diagnosis.
The weekly attack rate is determined during an 8-week assessment prior to therapy initiation
and at crossover.
Patients are randomly assigned to oral dichlorphenamide (DCP) or placebo for 9 weeks and
then cross to the alternate treatment. Patients on DCP at baseline continue on the same
dose; those on acetazolamide (ACZ) at baseline receive a DCP dose equivalent to one fifth of
the ACZ dose.
;
Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01939561 -
Lamotrigine as Treatment of Myotonia
|
Phase 3 | |
| Completed |
NCT02336477 -
Mexiletine and Non Dystrophic Myotonias
|
Phase 3 | |
| Recruiting |
NCT04808388 -
Using MRI in Patients With Non-dystrophic Myotonia to Access Muscle Contractility
|
||
| Completed |
NCT02251457 -
Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1
|
Phase 1 |